4506.T Sumitomo Pharma (JPX) +28.88% to JPY 3,184.00 on 17 Feb 2026: volume key

The 4506.T stock surged 28.88% to JPY 3,184.00 on 17 Feb 2026 at market close on the JPX, driven by heavy trading and strong underlying earnings metrics. Volume reached 38,215,500.00 shares versus an average of 9,460,054.00, marking this as one of the market’s most active names. Traders and analysts are watching follow-through as the move lifted the stock well above its 50-day average of JPY 2,391.52 and 200-day average of JPY 1,661.94, a sharp technical shift for the Healthcare sector in Japan.

4506.T stock intraday summary

Sumitomo Pharma Co., Ltd. (4506.T) closed at JPY 3,184.00, up JPY 713.50 or 28.88% on 17 Feb 2026. The session range was JPY 2,914.00—JPY 3,288.00, with an opening print at JPY 3,161.00 and previous close JPY 2,470.50. Market capitalisation sits near JPY 1,180,147,488,397.00, and traded volume of 38,215,500.00 represents a 4.04x jump versus average volume, underlining its “most active” status on the JPX.

Drivers behind the move and latest 4506.T news

The jump followed positive market attention and rotation into healthcare stocks, with Sumitomo Pharma highlighted on exchange wrap reports. Heavy buying was reported in end‑of‑day trade and the stock was singled out in Japan session commentary. See market summaries on investing.com for context: source and source. Increased volume and recent strategic alliances in R&D likely amplified investor interest.

4506.T stock fundamentals and valuation

Sumitomo Pharma posts trailing EPS of JPY 389.35 and a P/E around 7.63 on the latest quote, signalling strong earnings power relative to price. Key metrics include a price to sales of 2.60, price to book 4.08, and return on equity 48.92% (TTM). Debt to equity is 0.90, interest coverage 3.27, and current ratio 1.40, showing manageable balance sheet risk for the sector. Analysts should weigh the low P/E against higher PB and elevated intangibles exposure before assigning a valuation multiple.

Technical setup and trading signals for 4506.T stock

Technically the stock is overbought with RSI 70.82 and CCI 321.48, and momentum indicators show strong buying (MACD histogram 58.41). Price cleared the 50-day (JPY 2,391.52) and 200-day (JPY 1,661.94) moving averages with a gap in session. On‑balance volume jumped to 63,324,100.00, confirming demand. Short-term traders should watch intraday support near JPY 2,914.00 and resistance at the session high JPY 3,288.00.

Meyka AI grade and model forecast for 4506.T stock

Meyka AI rates 4506.T with a score out of 100: Meyka AI rates 4506.T with a score out of 100 — 74.05 / B+ — BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly value of JPY 2,368.14, a quarterly figure of JPY 2,165.69, and a one‑year view of JPY 809.27. Compared with the current price JPY 3,184.00, the monthly projection implies an approximate downside of -25.65%. Forecasts are model‑based projections and not guarantees.

Price targets, risks and sector context

Analyst consensus is limited, so we propose scenario targets: conservative JPY 2,700.00, base JPY 3,500.00, and bullish JPY 4,200.00. Key risks include setback in drug approvals, regulatory news, or margin pressure from R&D spend. Sector comparison: Healthcare peers trade on average P/E ~18.62 in Japan, so Sumitomo Pharma’s P/E 7.63 suggests value but with higher intangible assets and inventory days to monitor.

Final Thoughts

4506.T stock closed the most active session on the JPX on 17 Feb 2026, rising 28.88% to JPY 3,184.00 on volume 38,215,500.00. The move reflects heavy buyer interest, strong trailing EPS (JPY 389.35) and a low P/E of 7.63, but technicals show short‑term overbought conditions. Meyka AI’s grade (74.05 / B+ / BUY) highlights favourable earnings and sector positioning, while the model projects a monthly figure of JPY 2,368.14, implying near‑term downside of about -25.65% from today’s price. Investors should treat the current rally as a liquidity‑driven event and balance upside targets (JPY 3,500.00—4,200.00) against catalyst risk and potential mean reversion. For active traders, watch intraday support JPY 2,914.00 and the session high JPY 3,288.00. For longer horizon investors, verify clinical and regulatory updates and monitor sector flows before repositioning. Meyka AI provides this AI-powered market analysis platform data to inform, not to advise.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.